TMEM252: A Potential Drug Target and Biomarker for Wilson Disease

Target Name: TMEM252

NCBI ID: G169693

TMEM252

TMEM252: A Potential Drug Target and Biomarker for Wilson Disease

Wilson disease is a genetic disorder that affects the liver and other organs, leading to a range of symptoms such as jaundice, liver damage, and even liver cancer. The condition is caused by a deficiency of dystrophin, a protein that helps keep the liver healthy. Without dystrophin, the liver breaks down and replaces it with scar tissue, leading to the development of the disease.

Recent studies have identified TMEM252, a protein that is expressed in the liver, as a potential drug target and biomarker for Wilson disease. TMEM252 is a transmembrane protein that is located in the endoplasmic reticulum and is involved in the regulation of cellular processes such as protein synthesis, localization, and degradation.

One of the key functions of TMEM252 is its role in the regulation of dystrophin levels in the liver. Dystrophin is a protein that helps keep the liver healthy by breaking down and replacing it with scar tissue. However, in Wilson disease, the liver does not properly break down dystrophin, leading to a build-up of scar tissue and the development of the disease.

Research has shown that TMEM252 plays a key role in the regulation of dystrophin levels in the liver by interacting with its downstream target, p16. p16 is a protein that is involved in the regulation of cellular processes such as cell growth, apoptosis, and angiogenesis. TMEM252 has been shown to physically interact with p16 and to regulate its activity.

In addition to its role in regulating dystrophin levels, TMEM252 has also been shown to be involved in the regulation of other cellular processes. For example, it has been shown to be involved in the regulation of protein synthesis and localization, as well as in the regulation of cell cycle progression.

The potential implications of TMEM252 as a drug target and biomarker for Wilson disease are significant. If TMEM252 is successful in treating Wilson disease, it could be used to treat a wide range of liver and other organs affected by the disease. In addition, TMEM252 could also be used as a biomarker to diagnose the disease and to monitor the effectiveness of treatments.

While further research is needed to fully understand the potential implications of TMEM252 as a drug target and biomarker for Wilson disease, it is clear that it has the potential to revolutionize the treatment of this disease. Further studies are needed to determine the exact mechanisms by which TMEM252 interacts with p16 and to explore its potential as a drug and biomarker.

Protein Name: Transmembrane Protein 252

The "TMEM252 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM252 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets